Where OptimizeRx Stands With Analysts

Throughout the last three months, 4 analysts have evaluated OptimizeRx OPRX, offering a diverse set of opinions from bullish to bearish.

Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 1 2 1 0 0
Last 30D 1 1 0 0 0
1M Ago 0 0 0 0 0
2M Ago 0 0 0 0 0
3M Ago 0 1 1 0 0

The 12-month price targets, analyzed by analysts, offer insights with an average target of $15.5, a high estimate of $17.00, and a low estimate of $13.00. This current average has increased by 14.81% from the previous average price target of $13.50.

price target chart

Analyzing Analyst Ratings: A Detailed Breakdown

A clear picture of OptimizeRx's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
David Grossman Stifel Maintains Buy $13.00 $13.00
Sean Dodge RBC Capital Maintains Outperform $17.00 -
Sean Dodge RBC Capital Raises Outperform $17.00 $14.00
Stephanie Davis Barclays Announces Equal-Weight $15.00 -

Key Insights:

  • Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to OptimizeRx. This information provides a snapshot of how analysts perceive the current state of the company.
  • Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of OptimizeRx compared to the broader market.
  • Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of OptimizeRx's stock. This examination reveals shifts in analysts' expectations over time.

Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of OptimizeRx's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.

Stay up to date on OptimizeRx analyst ratings.

If you are interested in following small-cap stock news and performance you can start by tracking it here.

Unveiling the Story Behind OptimizeRx

OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its products offering are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.

A Deep Dive into OptimizeRx's Financials

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Revenue Growth: OptimizeRx's remarkable performance in 3 months is evident. As of 30 September, 2023, the company achieved an impressive revenue growth rate of 8.26%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.

Net Margin: OptimizeRx's net margin excels beyond industry benchmarks, reaching -17.54%. This signifies efficient cost management and strong financial health.

Return on Equity (ROE): OptimizeRx's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -2.47%, the company showcases efficient use of equity capital and strong financial health.

Return on Assets (ROA): OptimizeRx's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -2.34% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: OptimizeRx's debt-to-equity ratio is below the industry average at 0.0, reflecting a lower dependency on debt financing and a more conservative financial approach.

How Are Analyst Ratings Determined?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
▲▼
ticker
▲▼
name
▲▼
Price Target
▲▼
Upside/Downside
▲▼
Recommendation
▲▼
Firm
▲▼
Posted In: Analyst RatingsBZI-AAR
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!